Drugs / CV9201
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00923312 | May 2009 → Feb 2012 | non-small cell lung carcinoma | CureVac | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2011-11-07 | CureVac | Results CureVac presents clinical results of a Phase I/IIa trial in non-small cell lung cancer (NSCLC) curevac.com ↗
The results suggest that CV9201 is safe, well tolerated and biologically active. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2011-11-07 | CureVac | CureVac presents clinical results of a Phase I/IIa trial in non-small cell lung cancer (NSCLC) curevac.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CV9201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00923312 ↗ |
| Modality | Messenger RNA (mRNA) | “CV9201 is an mRNA-based vaccine for the treatment of human NSCLC” NCT00923312 ↗ |